or Try an Advanced Search...

    Technical Analysis for BRNS - Barinthus Biotherapeutics plc

    Grade Last Price % Change Price Change
    F 2.50 2.93% 0.07
    BRNS closed up 2.93 percent on Friday, April 26, 2024, on 28 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 10
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical BRNS trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion 2.93%
    Down 3 Days in a Row Weakness 2.93%
    Gapped Down Weakness 2.93%
    Oversold Stochastic Weakness 2.93%
    Narrow Range Bar Range Contraction -0.40%
    Wide Bands Range Expansion -0.40%
    Oversold Stochastic Weakness -0.40%
    Older End-of-Day Signals for BRNS ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 10 DMA about 15 hours ago
    Rose Above Previous Day's High about 16 hours ago
    10 DMA Resistance about 16 hours ago
    Up 5% about 16 hours ago
    Up 3% about 16 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    BRNS Chart by TradingView
    Basic chart:

    Profile

    Barinthus Biotherapeutics plc Description

    Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Immunotherapy Virotherapy Medical Research Carcinogens Papillomavirus HPV Immunotherapeutics Chronic Hbv Infection Human Papillomavirus Infection

    Is BRNS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 18 Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
    Mar 21 Barinthus Biotherapeutics GAAP EPS of -$1.91 beats by $0.05, revenue of $0.8M misses by $0.27M
    Mar 20 Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
    Jan 5 Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
    Dec 21 New partnership aims to advance vaccine against MERS coronavirus
    Nov 9 Barinthus Biotherapeutics GAAP EPS of -$0.37 beats by $0.15
    Nov 9 Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
    Nov 9 Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
    Nov 9 Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
    Nov 7 Barinthus stock falls 18%, day after changing name from Vaccitech
    See more BRNS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.09
    52 Week Low 1.64
    Average Volume 24,785
    200-Day Moving Average 2.81
    50-Day Moving Average 2.70
    20-Day Moving Average 2.83
    10-Day Moving Average 2.56
    Average True Range 0.26
    RSI (14) 44.13
    ADX 24.01
    +DI 21.11
    -DI 16.78
    Chandelier Exit (Long, 3 ATRs) 3.38
    Chandelier Exit (Short, 3 ATRs) 3.09
    Upper Bollinger Bands 3.60
    Lower Bollinger Band 2.06
    Percent B (%b) 0.29
    BandWidth 54.48
    MACD Line -0.07
    MACD Signal Line -0.01
    MACD Histogram -0.0567
    Fundamentals Value
    Market Cap 96.5 Million
    Num Shares 38.6 Million
    EPS -1.45
    Price-to-Earnings (P/E) Ratio -1.72
    Price-to-Sales 13.61
    Price-to-Book 0.50
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.80
    Resistance 3 (R3) 2.80 2.70 2.75
    Resistance 2 (R2) 2.70 2.62 2.70 2.73
    Resistance 1 (R1) 2.60 2.58 2.65 2.60 2.72
    Pivot Point 2.50 2.50 2.53 2.50 2.50
    Support 1 (S1) 2.40 2.42 2.45 2.40 2.28
    Support 2 (S2) 2.30 2.38 2.30 2.27
    Support 3 (S3) 2.20 2.30 2.25
    Support 4 (S4) 2.20